Success Metrics

Clinical Success Rate

77.8%

Based on 14 completed trials

Completion Rate

78%(14/18)

Active Trials

1(4%)

Results Posted

64%(9 trials)

Terminated

4(14%)

Phase Distribution

Ph early_phase_1

Ph not_applicable

32%

Ph phase_1

25%

Ph phase_2

21%

Ph phase_4

Ph phase_3

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution28 total trials

Early Phase 1First-in-human

2(7.1%)

Phase 1Safety & dosage

7(25.0%)

Phase 2Efficacy & side effects

6(21.4%)

Phase 3Large-scale testing

2(7.1%)

Phase 4Post-market surveillance

2(7.1%)

N/ANon-phased studies

9(32.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

66.7%

14 of 21 finished

Non-Completion Rate

33.3%

7 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(2)

Completed(14)

Terminated(7)

Other(5)

Detailed Status

Completed14

unknown5

Terminated4

Withdrawn3

Enrolling by invitation1

Recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

77.8%

Most Advanced

Phase 4

Trials by Phase

Early Phase 12 (7.1%)

Phase 17 (25.0%)

Phase 26 (21.4%)

Phase 32 (7.1%)

Phase 42 (7.1%)

N/A9 (32.1%)

Trials by Status

enrolling_by_invitation14%

recruiting14%

completed1450%

withdrawn311%

terminated414%

unknown518%

Recent Activity

1 active trials

Showing 5 of 28

enrolling_by_invitationearly_phase_1

Representation of Spatiotemporal Information in Human Episodic Memory and Navigation

NCT07423923

completedphase_1

Clinical Trials (28)

Showing 20 of 28 trialsScroll for more

NCT07423923Early Phase 1

Representation of Spatiotemporal Information in Human Episodic Memory and Navigation

Enrolling By Invitation

NCT04999449Phase 1

Nebulizer Delivery of Intranasal Scopolamine

Completed

NCT04366518Early Phase 1

Toward a Computationally-Informed, Personalized Treatment for Hallucinations

Recruiting

NCT06014385Phase 1

PET and MRI Imaging With Scopolamine at the Muscarinic M1 Receptor

Withdrawn

NCT04211961Phase 2

Scopolamine in Bipolar Depression

Completed

NCT04666701Phase 2

Efficacy and Safety of Escócia Association in the Treatment of Acute Pain

Withdrawn

NCT03988530Phase 3

Prevention and Treatment of Nausea Associated With Motion Sickness in Senior Subjects

Completed

NCT03874130Phase 1

Scopolamine in Healthy Volunteers

Unknown

NCT01900301Phase 1

Generalization of Extinction Learning

Completed

NCT02918266Phase 1

TAK-071 Scopolamine-Induced Cognitive Impairment Study

Terminated

NCT03920644Phase 3

Study of the Safety and Efficacy of DPI-386 Nasal Gel on Ocean-Going Vessels

Unknown

NCT02625181Not Applicable

Real-time Decision Support for Postoperative Nausea and Vomiting (PONV) Prophylaxis

Completed

NCT03131050Phase 4

Effectiveness Study of Scopolamine Combined With Escitalopram in Patients With MDD

Completed

NCT01213355Phase 1

Scopolamine Challenge Study

Completed

NCT01613820Not Applicable

Ketamine and Scopolamine Infusions for Treatment-resistant Major Depressive Disorder

Withdrawn

NCT02155309Phase 2

Pharmacokinetic and Efficacy Profile Intranasal Scopolamine Spray

Terminated

NCT01312844Phase 2

A Study of the Use of IV Scopolamine to Augment the Efficacy of Electroconvulsive Therapy (ECT)

Terminated

NCT02051335Phase 1

Roflumilast and Donepezil to Reverse Scopolamine Induced Cognitive Deficits in Healthy Adults

Completed

NCT02968082Phase 4

The Effects of Preoperative Scopolamine Patch Application on the Postoperative Nausea and Vomiting in MVD Surgery

Unknown

NCT00369915Phase 2

The Antidepressant Efficacy of the Anticholinergic Scopolamine

Terminated

Drug Details

Intervention Type: DRUG
Total Trials: 28